TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: HIV status disclosure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: competence in BLS training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: systolic blood pressure >140 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of pain and bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benefit for bowel habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mechanical force required for cervical dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects (hot flushes and headaches)
Endpoint domain: Adverse events/effects
Primary endpoint: Smokers' ratings of implied safety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 48-week retention in care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral suppression (% with measured week 48 VL ≤ 500 copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident rate of inflammatory response (IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest tube bleeding at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D-dimer levels at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dexamethasone concentration in tendon tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total syndrome improving rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity attenuating rate
Endpoint domain: Adverse events/effects
Primary endpoint: therapeutic response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthodontic pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glomerular filtration rate declination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: disappearance of donor specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of perinatal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of suboptimal care among morbidity cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-min pegboard and ring test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average additional cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response in anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity of MCAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma uric acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abolition of SSV reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor sensory disturbance
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients receiving two hemoglobin A1c tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with waistlines monitored
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients recommended a smoking cessation drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: IMT of carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bleeding recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Emergency operations
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ITP
Endpoint domain: Adverse events/effects
Primary endpoint: Educational attainment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: depression improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Equivalence of QLQ-C30 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HCV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of acute otitis media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of postoperative emesis
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of emetic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: flow‐mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean PD change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AL change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum immunoreactive insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pulmonary function assessed by FOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: post‐intervention oral‐mucositis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CD4 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative virologic failure risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hearing threshold benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eligibility for repeat tube surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in re-insertion surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CRP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of progression of atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraocular Pressure (IOP) rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year crude and disease free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of pyelonephritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration-endurance performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective concentration and performance related activation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: prospective memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial polyp formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean time for absorption of 50% of the bioavailable dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity of cytology for detecting high-grade tumours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of cytology for detecting carcinoma in situ (CIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: decrease in fatigue symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fatigue
Primary endpoint: achievement of rehabilitation goals
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: mean morphine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dysphoric mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: supplementary diazepam administration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean bone mineral density in the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bone mineral density of the femoral neck, trochanter and total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IMA artery flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary Sodium Excretion (UNaV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical failures 1 year after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: anatomic failure 1 year after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mortality rate at 10 days
Endpoint domain: Mortality/survival
Primary endpoint: Night-time systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stable renal function at last follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in right and left maximum intima‐media thickness of the common carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-wk mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients achieving DLQI 0/1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attainment of a ≥ 4-point reduction in DLQI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PSEB (Positive Self-Efficacy Beliefs)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postoperative pain scores on PACU arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ten-year disease-free survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Blood Vitamin C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum triglycerides (TG) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of End-Stage Renal Disease (ESRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: time awake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NREM stage 3 sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: heart disease risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motor recovery as measured by the Brunnström‐Fugl‐Meyer test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-HPV 6/11 geometric mean titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Target Vessel Revascularization (TVR) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean intraoperative bleeding score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postinjection pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in median menstrual blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women with successful treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of vasomotor symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Time to pain return
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from pain at 27 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSS scoring system score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intact-PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in adjusted serum Ca levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: procedure performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Velocity of blood flow (VS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vascular diameter (VD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median effective dose of intranasal DEX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 response at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary pH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of mouthrinse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asymptomatic status one month after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of treatment for bleeding and prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percent reduction in partial seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Responder rate during the add-on phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Median time <70 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sexual risk behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uNGAL levels as predictive marker of AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: uIL-18 levels as predictive marker of AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean TIINE concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of recurrent cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RBC-AR level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RBC-S level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: complicated myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: congestive cardiac failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delivery within 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Median gestational age at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Poor pregnancy outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Total adverse events score
Endpoint domain: Adverse events/effects
Primary endpoint: mean overall MHQ score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MHQ function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Days to normalization of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal voluntary ventilation (MVV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MPS‐HAQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Glycosylated hemoglobin (HbA(1)c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-h post-prandial test (2HPPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HOMA-S
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall cost per 4 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of tobacco use initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appropriateness of OAC prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite wound complication frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage change in lumbar bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ongoing pregnancy rates
Endpoint domain: Life impact
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean symptom score during the first week after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain control during rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quit success
Endpoint domain: Mortality/survival
Primary endpoint: Use of cessation medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tophi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PtGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary albumin creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: NTproBNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complications after vein harvesting
Endpoint domain: Adverse events/effects
Primary endpoint: Vein harvesting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intraventricular hemorrhage (IVH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Air leak (e.g. pneumothorax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants reporting symptoms greatly improved
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: professionals' knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: professionals' practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: professionals' attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kaplan-Meier kidney survival
Endpoint domain: Mortality/survival
Primary endpoint: Urine protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinical improvement measured by EDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver fibrosis improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Liver fibrosis progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Locoregional Recurrence-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: reduction in 2-year risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dietary fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of clinical malaria episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Analgesics use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful treatment of migraine headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of MV repair at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical assessment of inlays as clinically excellent or acceptable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal discoloration and integrity deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean preferred gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depth of probing of periodontal pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dental pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pyridinoline excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical parameters of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected visual acuity of 1.0 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction rated good
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: severe WMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: combined outcomes of total mortality and severe WMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: left ventricular function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death from anesthesia
Endpoint domain: Mortality/survival
Primary endpoint: Severe pneumonia
Endpoint domain: Adverse events/effects